Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | A prospective trial of radiation-free chemotherapy in high- and low-risk HL

Jan Maciej Zaucha • 16 Jun 2024
EHA 2024
Hodgkin Lymphoma Lymphoma Antibodies Nivolumab

Jan Maciej Zaucha, MD, Medical University of Gdansk, Gdańsk, Poland, discusses the first prospective trial using modern techniques to evaluate radiotherapy-free treatment in patients with high- and low-risk Hodgkin lymphoma (HL). The study found that post-chemotherapy PET analysis was more important than interim PET for low-risk patients, and adding immunotherapy might overcome chemotherapy resistance in high-risk patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jan Maciej Zaucha

1:10
The sensitization of immune checkpoint inhibitors with subsequent chemotherapy in R/R HL
Jan Maciej Zaucha • 16 Jun 2024

Related Videos

1:10
The sensitization of immune checkpoint inhibitors with subsequent chemotherapy in R/R HL
Jan Maciej Zaucha • 16 Jun 2024
1:30
The use of targeted drug therapy for aggressive lymphoma
Mariana Bastos • 14 Jun 2024
2:06
Reducing CRS following epcoritamab in R/R FL: insights from an optimization cohort of EPCORE NHL-1
Umberto Vitolo • 15 Jun 2024
1:29
Insights into the uses of ibrutinib for patients with Waldenström’s macroglobulinemia
Ramon Garcia-Sanz • 16 Jun 2024
The content of VJHemOnc is intended for healthcare professionals